Biogen: Gewinn 44 Cent pro Aktie! - 500 Beiträge pro Seite
eröffnet am 10.10.00 23:27:42 von
neuester Beitrag 11.10.00 18:28:49 von
neuester Beitrag 11.10.00 18:28:49 von
Beiträge: 10
ID: 266.051
ID: 266.051
Aufrufe heute: 0
Gesamt: 484
Gesamt: 484
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 3683 | |
| vor 45 Minuten | 2319 | |
| vor 34 Minuten | 1977 | |
| vor 33 Minuten | 1715 | |
| vor 48 Minuten | 946 | |
| vor 59 Minuten | 901 | |
| heute 07:24 | 839 | |
| vor 1 Stunde | 776 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.042,60 | +0,21 | 159 | |||
| 2. | 2. | 0,1815 | -2,16 | 50 | |||
| 3. | 6. | 7,7000 | -8,33 | 45 | |||
| 4. | 44. | 481,20 | +0,46 | 31 | |||
| 5. | 4. | 166,58 | +0,19 | 26 | |||
| 6. | Neu! | 27,08 | +0,17 | 24 | |||
| 7. | 16. | 18,000 | +2,56 | 22 | |||
| 8. | 15. | 10,700 | +2,88 | 22 |
Feedback
Biogen Reports Third Quarter 2000 Results
Collaborations Bolster the Company`s Pipeline Development Efforts
CAMBRIDGE, Mass., Oct. 10 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN - news) today reported financial
results for the third quarter of 2000. For the three months ended September 30, 2000, the Company reported net
income of $68,381,000, an increase of 10 percent compared to the same period in 1999, resulting in $0.44 per
share. Revenues for the quarter were $233,754,000, up 12 percent over the third quarter of last year.) James C. Mullen, Biogen`s President and
Chief Executive Officer, said, "With its proven results and broad-based efficacy, AVONEX® remains the
worldwide drug of choice among people with multiple sclerosis (MS) and their
physicians. This quarter, we saw global product revenue growth of 18 percent
year-over-year.
Das ist ebenfalls ein Cent mehr als erwartet.
Collaborations Bolster the Company`s Pipeline Development Efforts
CAMBRIDGE, Mass., Oct. 10 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN - news) today reported financial
results for the third quarter of 2000. For the three months ended September 30, 2000, the Company reported net
income of $68,381,000, an increase of 10 percent compared to the same period in 1999, resulting in $0.44 per
share. Revenues for the quarter were $233,754,000, up 12 percent over the third quarter of last year.) James C. Mullen, Biogen`s President and
Chief Executive Officer, said, "With its proven results and broad-based efficacy, AVONEX® remains the
worldwide drug of choice among people with multiple sclerosis (MS) and their
physicians. This quarter, we saw global product revenue growth of 18 percent
year-over-year.
Das ist ebenfalls ein Cent mehr als erwartet.
Na klasse, lagen die Flüsterschätzungen nicht bei 46 Cents????
A-Friend
A-Friend
weitere News:
Ursprung: http://www.thestreet.com/_yahoo/stocks/biotech/1118509.html
Biogen Beats Earnings Estimates as MS Drug Gains
By Dane Hamilton
Staff Reporter
10/10/00 5:42 PM ET
Biogen (BGEN:Nasdaq - news), one of the few profitable biotech companies, said Tuesday that third-quarter earnings rose 13%, slighly more than expected, pushed by rising U.S. sales of Avonex, a leading multiple sclerosis drug.
Biogen said earnings per share rose to 44 cents a share from 39 cents a share a year ago. The consensus analyst forcast for the Cambridge, Mass., biotech company was 43 cents a share, according to First Call/Thomson Financial.
Net income rose 10% to $68.3 million. Revenue rose 12% to $233.7 million, with Avonex sales rising 18% to $193 million.
Avonex, which generated 78% of Biogen`s 1999 revenue of $794.4 million, is facing increasing pressure in the European multiple sclerosis treatment market from Rebif, made by Switzerland`s Serono (SRA:NYSE - news), and Betaseron, which is marketed by Chiron (CHIR:Nasdaq - news) and Germany`s Schering. Sales in Europe, where Avonex holds about 35% of the market, rose 14% to $55 million.
But sales in the U.S., where Avonex is protected from competition until 2003, rose 19% to $138 million. The drug has about half the domestic MS market.
In response to worries about Avonex competition, Biogen is stepping up efforts to develop other products including Amevive for psoriasis, while seeking to broaden Avonex use in the multiple sclerosis market, particularly for early stages. It has also executed alliances with companies including Elan (ELN:NYSE - news).
"The positive results seen in primary progressive MS, a very aggressive form of the disease, are very encouraging," said Biogen in a release.
Biogen shares have fallen from a high of 129 in March at the height of the biotech bull market to close at 51 Tuesday, partly pushed down by worries over competition to Avonex.
Biogen said in a postearnings conference call that it expects to report 2000 operating earnings of around $1.70 a share, in line with analysts` forecasts.
rtzrtz66
Ursprung: http://www.thestreet.com/_yahoo/stocks/biotech/1118509.html
Biogen Beats Earnings Estimates as MS Drug Gains
By Dane Hamilton
Staff Reporter
10/10/00 5:42 PM ET
Biogen (BGEN:Nasdaq - news), one of the few profitable biotech companies, said Tuesday that third-quarter earnings rose 13%, slighly more than expected, pushed by rising U.S. sales of Avonex, a leading multiple sclerosis drug.
Biogen said earnings per share rose to 44 cents a share from 39 cents a share a year ago. The consensus analyst forcast for the Cambridge, Mass., biotech company was 43 cents a share, according to First Call/Thomson Financial.
Net income rose 10% to $68.3 million. Revenue rose 12% to $233.7 million, with Avonex sales rising 18% to $193 million.
Avonex, which generated 78% of Biogen`s 1999 revenue of $794.4 million, is facing increasing pressure in the European multiple sclerosis treatment market from Rebif, made by Switzerland`s Serono (SRA:NYSE - news), and Betaseron, which is marketed by Chiron (CHIR:Nasdaq - news) and Germany`s Schering. Sales in Europe, where Avonex holds about 35% of the market, rose 14% to $55 million.
But sales in the U.S., where Avonex is protected from competition until 2003, rose 19% to $138 million. The drug has about half the domestic MS market.
In response to worries about Avonex competition, Biogen is stepping up efforts to develop other products including Amevive for psoriasis, while seeking to broaden Avonex use in the multiple sclerosis market, particularly for early stages. It has also executed alliances with companies including Elan (ELN:NYSE - news).
"The positive results seen in primary progressive MS, a very aggressive form of the disease, are very encouraging," said Biogen in a release.
Biogen shares have fallen from a high of 129 in March at the height of the biotech bull market to close at 51 Tuesday, partly pushed down by worries over competition to Avonex.
Biogen said in a postearnings conference call that it expects to report 2000 operating earnings of around $1.70 a share, in line with analysts` forecasts.
rtzrtz66
@a-friend:
wen interessiert schon, was du flüsterst? die analysten haben das jedenfalls nicht geflüstert
wen interessiert schon, was du flüsterst? die analysten haben das jedenfalls nicht geflüstert
Sorry ... ich hab` die Quelle vergessen, aber es sollte halt schnell gehen, die meisten haben ja darauf gewartet ...
Trading Spotlight
Ich glaube, es wird sogar sehr viele interessieren! 
Warum so nervös? So schlecht sind die Zahlen auch nicht.
A-Friend
Warum so nervös? So schlecht sind die Zahlen auch nicht.
A-Friend
OHGOTT, die nächste Katastrophe. Hört das denn gar nicht mehr auf?
@ A-Friend:
Teilweise hast du schon Recht, das Flüsterschätzungen wichtig sind!
Bei Motorola muß ich aber Stock-Riese Recht geben!
Übrigen hat Biogen die Flüsterschätzungen getroffen!
Mit deinen Meinungen bist Du schon sehr negativ und manchmal auch unsachlich!
Teilweise hast du schon Recht, das Flüsterschätzungen wichtig sind!
Bei Motorola muß ich aber Stock-Riese Recht geben!
Übrigen hat Biogen die Flüsterschätzungen getroffen!
Mit deinen Meinungen bist Du schon sehr negativ und manchmal auch unsachlich!
mach5,
ich glaube nicht, daß mich Optimismus weiterbringt zur Zeit!
Zu Motorola:
erreicht wurden 26 Cents, Flüsterschätzung waren 27 Cents.
Ich sagte nur, die Flüsterchätzungen seien nicht erreicht worden, basta aus.
Da gibt es gar keine Diskussionen, es ist so.
Um es euch genehm zu machen:
der Markt kann durchaus eine kleine Bärenmarktrallye sehen, eine Trendwende sehe ich jedoch vorerst nicht.
Dazu gibt es zuviele Probleme auf Währungsebene, bei den Energiepreisen und bei den Unternehmensgewinnen.
KGVs jenseits von 80-100 sollten bald erledigt sein.
A-Friend
ich glaube nicht, daß mich Optimismus weiterbringt zur Zeit!
Zu Motorola:
erreicht wurden 26 Cents, Flüsterschätzung waren 27 Cents.
Ich sagte nur, die Flüsterchätzungen seien nicht erreicht worden, basta aus.
Da gibt es gar keine Diskussionen, es ist so.
Um es euch genehm zu machen:
der Markt kann durchaus eine kleine Bärenmarktrallye sehen, eine Trendwende sehe ich jedoch vorerst nicht.
Dazu gibt es zuviele Probleme auf Währungsebene, bei den Energiepreisen und bei den Unternehmensgewinnen.
KGVs jenseits von 80-100 sollten bald erledigt sein.
A-Friend
Hier mal zur Abwechslung eine gute Nachricht:
ursprung:http://www.cnetinvestor.com/yahoonews/newsitem-yahoo.asp?SYM…
US Bancorp Piper Jaffray Comments on YHOO, IMNX, RARE, BGEN, SPWX and NDB
By: US Bancorp Piper Jaffray
10/11/00 7:54:38 AM
...
Biogen, Inc. (BGEN – 51 1/2)
Buy; EPS 00E $1.75, 01E $2.04; Mkt Cap $7,916M; Avg Vol 2,888,000; Target $92 (45x 2001 EPS)
Modest Sequential Avonex Sales Growth In Third Quarter As Expected; Avonex Sales Of $193.2 Million Up 18% Compared To 3Q99, But Only Up 2% Compared To 2Q00; We Believe That Sales In The Fourth Quarter And In 2001 Will Benefit From The Recent CHAMPS Publication, Leading To Improved Sales Growth For Biogen; Additionally, Fourth Quarter Should Be Full Of Catalysts For Biogen; Reiterate Buy Rating And $92 Price Target
Gruss
rtzrtz66
ursprung:http://www.cnetinvestor.com/yahoonews/newsitem-yahoo.asp?SYM…
US Bancorp Piper Jaffray Comments on YHOO, IMNX, RARE, BGEN, SPWX and NDB
By: US Bancorp Piper Jaffray
10/11/00 7:54:38 AM
...
Biogen, Inc. (BGEN – 51 1/2)
Buy; EPS 00E $1.75, 01E $2.04; Mkt Cap $7,916M; Avg Vol 2,888,000; Target $92 (45x 2001 EPS)
Modest Sequential Avonex Sales Growth In Third Quarter As Expected; Avonex Sales Of $193.2 Million Up 18% Compared To 3Q99, But Only Up 2% Compared To 2Q00; We Believe That Sales In The Fourth Quarter And In 2001 Will Benefit From The Recent CHAMPS Publication, Leading To Improved Sales Growth For Biogen; Additionally, Fourth Quarter Should Be Full Of Catalysts For Biogen; Reiterate Buy Rating And $92 Price Target
Gruss
rtzrtz66
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 159 | ||
| 50 | ||
| 45 | ||
| 31 | ||
| 26 | ||
| 24 | ||
| 22 | ||
| 22 | ||
| 21 | ||
| 19 |
| Wertpapier | Beiträge | |
|---|---|---|
| 19 | ||
| 19 | ||
| 18 | ||
| 18 | ||
| 13 | ||
| 13 | ||
| 12 | ||
| 11 | ||
| 11 | ||
| 10 |
